Clinical Trial Update: Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment [Phase 3]

View source ↗

Summary

An active Phase 3 trial is evaluating Savolitinib in combination with Osimertinib versus platinum-based chemotherapy in patients with non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)
• Savolitinib (savolitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: ACTIVE_NOT_RECRUITING